Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.59 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387302 | 0.88 | EGFR (0.72) | EGFRTNNI3KNPC1ERBB3NPSR1 | |
| SCHEMBL3952295 | 0.83 | EGFR (0.66) | EGFRTNNI3KNPC1ERBB3HTT | |
| Hydrochloric Acid SCHEMBL2173883 | 0.82 | EGFR (0.64) | EGFRTNNI3KNPC1ERBB3HTT | |
| SCHEMBL8798667 | 0.82 | EGFR (0.61) | EGFRTNNI3KNPSR1HTTHIF1A | |
| SCHEMBL2782010 | 0.82 | EGFR (0.65) | EGFRTNNI3KNPC1ERBB3NPSR1 | |
| SCHEMBL28805101 | 0.81 | NPC1 (0.69) | EGFRTNNI3KNPC1ERBB3MKNK1 | |
| SCHEMBL857502 | 0.81 | NPC1 (0.63) | EGFRTNNI3KNPC1ERBB3MKNK1 | |
| SCHEMBL12510600 | 0.81 | NPC1 (0.51) | EGFRTNNI3KNPC1ERBB3THRB | |
| SCHEMBL20093470 | 0.81 | NPC1 (0.51) | EGFRTNNI3KNPC1ERBB3MKNK1 | |
| SCHEMBL691533 | 0.81 | EGFR (0.57) | EGFRTNNI3KNPC1ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011079343-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TECHNISCHE UNIVERSITAET WIEN (AT) | 2011-07-07 | — | — | WO | disclosed |
| EP-0733045-B1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| US-5880130-A | TREATMENT OF CELL-PROLIFERATION DISEASES | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
| EP-0733045-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015952-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | EGFR 888/4885TNNI3K 2596/4885NPC1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.